<DOC>
	<DOC>NCT03049852</DOC>
	<brief_summary>1. CBT-001 administered three times daily (TID) for 4 weeks has an acceptable safety profile when used in pterygium patients 2. CBT-001 administered TID for 4 weeks is more effective than the vehicle in reducing pterygium vascularity and inhibiting pterygium lesion growth 3. CBT-001 administered as topical ocular dosing displays negligible systemic drug exposure</brief_summary>
	<brief_title>Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium</brief_title>
	<detailed_description />
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Primary pterygium with moderate vascularity (Pterygium Hyperemia Grading Scale â‰¥ 3) Active ocular disease, corneal abnormalities other than pterygium, active ocular infection, or any ocular pathology unrelated to pterygium in either eye that could affect the assessment of the pterygium History of ocular herpes disease in either eye Any ocular surgical procedure within the last 3 months Female patients who are pregnant, nursing, or planning a pregnancy during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>